MA32319B1 - Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor - Google Patents

Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor

Info

Publication number
MA32319B1
MA32319B1 MA33370A MA33370A MA32319B1 MA 32319 B1 MA32319 B1 MA 32319B1 MA 33370 A MA33370 A MA 33370A MA 33370 A MA33370 A MA 33370A MA 32319 B1 MA32319 B1 MA 32319B1
Authority
MA
Morocco
Prior art keywords
mtor
useful
kinase inhibitors
triazine derivatives
compounds
Prior art date
Application number
MA33370A
Other languages
Arabic (ar)
English (en)
Inventor
Aranapakam M Venkatesan
Zecheng Chen
Christoph M Dehnhardt
Santos Osvaldo Dos
Santos Efren Guillermo Delos
Arie Zask
Jeroen C Verheijen
Joshua Aaron Kaplan
David J Richard
Semiramis Ayral-Kaloustian
Tarek S Mansour
Ariamala Gopalsamy
Kevin J Curran
Mengxiao Shi
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MA32319B1 publication Critical patent/MA32319B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des composés de formule i (i) dans laquelle : r1 représente (ii) ou (iii); et r2, r4 et r6-9 sont définis présentement, et sur des sels pharmaceutiquement acceptables et esters de ceux-ci. Ces composés inhibent la kinase p13 et mtor, et peuvent être utilisés pour traiter des maladies à médiation par la kinase p13 et mtor, telles qu'une diversité de cancers. L'invention porte également sur des procédés de fabrication et d'utilisation des composés de cette invention. L'invention porte également sur diverses compositions contenant les composés de cette invention.
MA33370A 2008-05-23 2010-11-23 Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor MA32319B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5566108P 2008-05-23 2008-05-23
PCT/US2009/044774 WO2009143313A1 (fr) 2008-05-23 2009-05-21 Composés triazines en tant qu'inhibiteurs de kinase p13 et de mtor

Publications (1)

Publication Number Publication Date
MA32319B1 true MA32319B1 (fr) 2011-05-02

Family

ID=40911929

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33370A MA32319B1 (fr) 2008-05-23 2010-11-23 Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor

Country Status (43)

Country Link
US (8) US20090304692A1 (fr)
EP (3) EP3216793B1 (fr)
JP (2) JP4948677B2 (fr)
KR (1) KR101331341B1 (fr)
CN (2) CN104230831B (fr)
AP (2) AP2775A (fr)
AR (2) AR071908A1 (fr)
AU (2) AU2009248993C1 (fr)
BR (1) BRPI0912294B8 (fr)
CA (2) CA2721692C (fr)
CL (2) CL2009001273A1 (fr)
CO (1) CO6311070A2 (fr)
CR (1) CR11757A (fr)
CU (1) CU23887B1 (fr)
CY (2) CY1118879T1 (fr)
DK (2) DK3216793T3 (fr)
DO (1) DOP2010000315A (fr)
EA (1) EA020317B1 (fr)
EC (2) ECSP10010624A (fr)
ES (2) ES2625467T3 (fr)
GE (1) GEP20125589B (fr)
HR (2) HRP20170637T1 (fr)
HU (1) HUE043331T2 (fr)
IL (2) IL209061A0 (fr)
LT (2) LT2294072T (fr)
MA (1) MA32319B1 (fr)
ME (1) ME01111B (fr)
MX (1) MX2010012808A (fr)
MY (1) MY155653A (fr)
NI (1) NI201000198A (fr)
NZ (1) NZ588526A (fr)
PA (2) PA8828201A1 (fr)
PE (2) PE20091943A1 (fr)
PL (1) PL3216793T3 (fr)
PT (2) PT3216793T (fr)
RS (2) RS55960B1 (fr)
SA (1) SA109300314B1 (fr)
SI (2) SI3216793T1 (fr)
TR (1) TR201906123T4 (fr)
TW (2) TW201008949A (fr)
UA (1) UA99361C2 (fr)
WO (2) WO2009143313A1 (fr)
ZA (1) ZA201007204B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022381B2 (en) * 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
AP2775A (en) * 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010096619A1 (fr) * 2009-02-23 2010-08-26 Wyeth Llc Procédé, purification et cristallisation de 1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phényl]urée
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2013502429A (ja) * 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
WO2011087812A1 (fr) * 2009-12-21 2011-07-21 Vanderbilt University Analogues de 3-((2-amidoéthyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate d'alkyle comme agonistes sélectifs pour m1 et leurs procédés de fabrication et d'utilisation
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
CA2825825A1 (fr) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibiteurs de kinase mtor en tant qu'agents antiviraux
CA2825028A1 (fr) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Composes heterocycliques en tant qu'inhibiteurs de pi3 kinase
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
CN102887867B (zh) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 一类三嗪类化合物、该化合物的制备方法及其用途
ES2609606T3 (es) * 2011-09-21 2017-04-21 Cellzome Limited Derivados de urea y carbamato de 2-morfolino-1,3,5-triazina como inhibidores de mTOR para el tratamiento de enfermedades inmunológicas o proliferativas
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
CN102659765B (zh) * 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
WO2014005182A1 (fr) * 2012-07-04 2014-01-09 Monash University Inhibiteurs de phosphoinositide 3-kinase (pi3k)
WO2014016849A2 (fr) * 2012-07-23 2014-01-30 Sphaera Pharma Pvt. Ltd. Nouveaux composés de triazine
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
MA39734B1 (fr) 2014-03-14 2019-07-31 Pfizer Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
WO2016049774A1 (fr) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urée et composés à base de bis-urée et analogues de ceux-ci utiles dans le traitement de maladies ou trouble à médiation par récepteur des androgènes
MX2017004580A (es) 2014-10-10 2017-06-27 Pfizer Combinaciones de auristatina sinergica.
EP3221307B1 (fr) 2014-11-20 2019-07-24 Council of Scientific & Industrial Research Nouveaux inhibiteurs de pi3k à base de 1,3,5 -triazine en tant que agents anticancéreux et un procédé pour leur préparation
HRP20211446T1 (hr) * 2014-12-17 2021-12-24 Pfizer Inc. Formulacije inhibitora pi3k/mtor za intravensko davanje
CN104725361B (zh) * 2015-04-09 2017-05-31 江苏富比亚化学品有限公司 一种受阻胺类光稳定剂3346的制备方法
SG11201809760TA (en) * 2016-05-12 2018-12-28 Nanjing Shiqi Pharmaceutical Co Ltd Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
ES2863250T3 (es) * 2016-05-18 2021-10-11 Torqur Ag Tratamiento de trastornos neurológicos
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
IT201700047189A1 (it) * 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
RS62663B1 (sr) 2017-08-25 2021-12-31 Pfizer Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
KR102022323B1 (ko) 2018-03-30 2019-09-18 정하윤 트리아진 화합물 및 이의 용도
MX2020013238A (es) * 2018-06-07 2021-02-22 Pfizer Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea.
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN109942562B (zh) * 2019-02-27 2022-02-08 江西科技师范大学 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
MX2022012339A (es) * 2020-04-07 2022-10-27 Mei Pharma Inc Preparacion de un 1,3,5-triazinil benzimidazol.
WO2022159981A1 (fr) * 2021-01-25 2022-07-28 Athos Therapeutics, Inc. Composés de triazine et leurs procédés de fabrication et d'utilisation
KR20220138575A (ko) 2021-04-06 2022-10-13 부산대학교병원 전좌 신장암 치료 또는 예방용 약물 스크리닝 방법
CN113200969B (zh) * 2021-05-19 2022-11-25 中国药科大学 一种PI3Kα选择性抑制剂及其制备方法和应用
WO2023009438A1 (fr) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phényl]urée (gedatolisib) et ses combinaisons pour une utilisation dans le traitement du cancer
CN115109049B (zh) * 2022-08-12 2023-08-15 江西科技师范大学 含芳基脲结构的三嗪类化合物及其应用
CN115557908B (zh) * 2022-09-28 2024-10-15 九江学院 一种含硫连接键的三嗪类衍生物及其合成方法、用途
CN116102545B (zh) * 2023-02-01 2025-03-25 贵州医科大学 一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
CN116239580B (zh) * 2023-03-06 2025-05-23 中国药科大学 三嗪类化合物及其制备方法、药物组合物和应用
WO2025116280A1 (fr) * 2023-11-29 2025-06-05 주식회사 펩토이드 Nouveaux composés de fluorotriazine symétriques et leurs utilisations médicales ou biologiques
WO2025128712A1 (fr) 2023-12-12 2025-06-19 Celcuity Inc. Traitement de maladies oculaires à l'aide de 1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl)phényl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phényl]urée
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders
CN120004875A (zh) * 2025-04-22 2025-05-16 中国药科大学 靶向降解磷脂酰肌醇3-激酶的化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100563514B1 (ko) * 1997-07-24 2006-03-27 젠야쿠코교가부시키가이샤 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
EP1389617B1 (fr) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2006217742A1 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
AP2775A (en) * 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors

Also Published As

Publication number Publication date
IL209061A0 (en) 2011-01-31
RS58724B1 (sr) 2019-06-28
NZ588526A (en) 2012-08-31
US8748421B2 (en) 2014-06-10
DK2294072T3 (en) 2017-05-15
US9174963B2 (en) 2015-11-03
BRPI0912294A2 (pt) 2015-10-20
ECSP10010623A (es) 2010-12-30
US8039469B2 (en) 2011-10-18
ES2728163T3 (es) 2019-10-22
EP2294072B1 (fr) 2017-03-29
ES2625467T3 (es) 2017-07-19
CN102036995A (zh) 2011-04-27
BRPI0912294B1 (pt) 2019-11-12
US20110312955A1 (en) 2011-12-22
HUE043331T2 (hu) 2019-08-28
CN102036995B (zh) 2014-09-17
EP3216793B1 (fr) 2019-03-27
HK1157328A1 (en) 2012-06-29
DK3216793T3 (da) 2019-05-06
PA8828101A1 (es) 2009-12-16
ZA201007204B (en) 2011-12-28
CA2721710A1 (fr) 2009-11-26
CU20100229A7 (es) 2011-11-15
CR11757A (es) 2010-11-30
ME01111B (me) 2013-03-20
LT3216793T (lt) 2019-05-10
CL2009001273A1 (es) 2009-11-27
CY1118879T1 (el) 2018-01-10
IL209060A0 (en) 2011-01-31
CA2721692C (fr) 2014-01-14
CN104230831B (zh) 2016-08-24
IL209060A (en) 2014-05-28
WO2009143317A1 (fr) 2009-11-26
KR101331341B1 (ko) 2013-11-19
HRP20190680T1 (hr) 2019-06-14
US8859542B2 (en) 2014-10-14
MY155653A (en) 2015-11-13
RS55960B1 (sr) 2017-09-29
BRPI0912294B8 (pt) 2021-05-25
KR20110002485A (ko) 2011-01-07
MX2010012808A (es) 2010-12-21
US8445486B2 (en) 2013-05-21
TW201011010A (en) 2010-03-16
EP3216793A1 (fr) 2017-09-13
US20140248239A1 (en) 2014-09-04
US20090291079A1 (en) 2009-11-26
PE20091943A1 (es) 2009-12-19
US20130005723A1 (en) 2013-01-03
ECSP10010624A (es) 2010-12-30
AU2009248993A1 (en) 2009-11-26
EP2300483A1 (fr) 2011-03-30
SA109300314B1 (ar) 2012-09-26
JP4948677B2 (ja) 2012-06-06
TWI389906B (zh) 2013-03-21
PL3216793T3 (pl) 2019-09-30
PT3216793T (pt) 2019-05-30
GEP20125589B (en) 2012-07-25
AU2009248997A1 (en) 2009-11-26
US8217036B2 (en) 2012-07-10
SI3216793T1 (sl) 2019-06-28
EP2294072A1 (fr) 2011-03-16
EA201071232A1 (ru) 2011-06-30
NI201000198A (es) 2011-05-09
CU23887B1 (es) 2013-04-19
AU2009248993C1 (en) 2013-10-03
SI2294072T1 (sl) 2017-05-31
CA2721692A1 (fr) 2009-11-26
HK1203199A1 (en) 2015-10-23
US20150011752A1 (en) 2015-01-08
PA8828201A1 (es) 2009-12-16
HRP20170637T1 (hr) 2017-06-30
TR201906123T4 (tr) 2019-05-21
AU2009248993B2 (en) 2011-07-07
JP2011520979A (ja) 2011-07-21
WO2009143313A1 (fr) 2009-11-26
AP2775A (en) 2013-09-30
DOP2010000315A (es) 2010-12-15
US8575159B2 (en) 2013-11-05
CO6311070A2 (es) 2011-08-22
AR071908A1 (es) 2010-07-21
CY1121699T1 (el) 2020-07-31
AP2010005452A0 (en) 2010-12-31
US20130109670A1 (en) 2013-05-02
PE20091957A1 (es) 2009-12-30
US20090304692A1 (en) 2009-12-10
EA020317B1 (ru) 2014-10-30
TW201008949A (en) 2010-03-01
AR071909A1 (es) 2010-07-21
PT2294072T (pt) 2017-05-29
JP2011522802A (ja) 2011-08-04
CL2009001274A1 (es) 2009-10-16
UA99361C2 (uk) 2012-08-10
LT2294072T (lt) 2017-06-12
US20130315865A1 (en) 2013-11-28
AP2010005453A0 (en) 2010-12-31
CN104230831A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
MA32319B1 (fr) Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor
DK2250172T3 (da) Pyrrolopyrazinkinaseinhibitorer
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
MA32811B1 (fr) Nouveaux composés
TN2010000131A1 (en) Polo-like kinase inhibitors
EA201170521A1 (ru) Новые соединения
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2009010595A (es) Derivados de pirrolopirimidina.
MY150542A (en) Cmet inhibitors
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
NZ579928A (en) Fluorinated derivatives of deferiprone
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
MX2012008141A (es) Compuestos y metodos.
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives